Achillion Pharmaceuticals, Inc. Sustainability Profile
Achillion Pharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 1998, the company has made significant strides in developing innovative therapies, particularly in the fields of infectious diseases and rare genetic disorders. Achillion is renowned for its cutting-edge research and development, focusing on small molecule drugs that target specific viral infections and complement-mediated diseases. With a strong emphasis on advancing treatments for hepatitis C and other viral infections, Achillion has positioned itself as a leader in the market. The company’s unique approach to drug development, combined with its commitment to scientific excellence, has led to notable achievements, including strategic partnerships and a robust pipeline of potential therapies. As it continues to expand its operational reach, Achillion Pharmaceuticals remains dedicated to improving patient outcomes through groundbreaking medical solutions.
DitchCarbon Score
How does Achillion Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Achillion Pharmaceuticals, Inc.'s score of 93 is higher than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Achillion Pharmaceuticals, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. However, the company is part of a corporate family that includes AstraZeneca PLC, from which it inherits climate commitments and initiatives. Achillion's climate strategy is influenced by its relationship with AstraZeneca, which has set ambitious targets for carbon reduction. These targets are cascaded down to Achillion as a current subsidiary. AstraZeneca has committed to significant emissions reductions across its operations, which include Scope 1, 2, and 3 emissions. The specific details of these targets and the associated emissions data are not directly reported for Achillion but reflect the broader commitments of its parent company. Additionally, Achillion benefits from initiatives such as the Science Based Targets initiative (SBTi) and the CDP, which are also linked to AstraZeneca and Alexion Pharmaceuticals, Inc. These initiatives aim to enhance transparency and accountability in climate action, although specific reduction targets for Achillion are not detailed. In summary, while Achillion Pharmaceuticals, Inc. does not provide its own emissions data or specific reduction targets, it aligns with the climate commitments of its parent company, AstraZeneca PLC, which is actively working towards substantial emissions reductions and sustainability goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 298,498,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 322,319,000 | 000,000,000 | 000,000,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Achillion Pharmaceuticals, Inc.'s Industry?
How Carbon Intensive is Achillion Pharmaceuticals, Inc.'s Location?
Achillion Pharmaceuticals, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Achillion Pharmaceuticals, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
